DRUG
What one share of Bright Minds Biosciences holds
Pharmaceutical Preparations
The Company is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other central nervous system (CNS) disorders.
Bright Minds Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-09-30; the balance sheet is as of 2025-09-30.
| Profit | −$1.27 |
|---|---|
| Cash and investments | $7.80 |
| Book value | $7.72 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$0.49 | — | −$0.30 | — | $0.76 |
| 2021 | — | −$3.82 | — | −$3.23 | — | $6.47 |
| 2022 | — | −$4.74 | — | −$4.31 | — | $2.18 |
| 2023 | — | −$1.47 | — | −$1.40 | — | $1.09 |
| 2024 | — | −$0.48 | — | −$0.32 | — | $0.91 |
| 2025 | — | −$1.27 | — | −$0.90 | — | $7.72 |